Omalizumab Cuts Down Hospital Visits

Published Online: Friday, July 1, 2005

Patients may benefit from adding omalizumab (Xolair) to their asthma treatment if they have persistent asthma that is not being controlled. For the study, 419 patients with acute asthma were randomly given omalizumab or placebo for 28 weeks. All of the participants were taking high doses of inhaled corticosteroids plus long-acting beta2 agonists, and two thirds were also receiving controller medications, including 22% who were taking oral corticosteroids.

Reporting the findings during the recent annual meeting of the American Academy of Allergy, Asthma, and Immunology, the researchers found that omalizumab was linked with a 26% reduction in the rate of clinically significant asthma exacerbations, compared with placebo. Furthermore, the medication considerably lowered the occurrence of severe asthma attacks and emergency room visits. Lead researcher Phillip Korenblat, MD, said omalizumab led to "meaningful improvement"in asthmarelated quality of life. Omalizumab "should be considered in this group of patients with severe persistent asthma who continue to have unmet needs despite the best available therapy,"he added.

Latest Articles
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
President Barack Obama’s fiscal year 2017 budget proposal calls for an additional $1.1 billion to combat the nation’s spiraling opioid epidemic.
Baxter International is voluntarily recalling intravenous solution due to leaking containers and the potential for particulate matter.
Latest Issues